Development of the International Severe Asthma Registry (ISAR): A Modified Delphi Study.


Journal

The journal of allergy and clinical immunology. In practice
ISSN: 2213-2201
Titre abrégé: J Allergy Clin Immunol Pract
Pays: United States
ID NLM: 101597220

Informations de publication

Date de publication:
02 2019
Historique:
received: 17 04 2018
revised: 30 07 2018
accepted: 13 08 2018
pubmed: 5 9 2018
medline: 13 6 2020
entrez: 5 9 2018
Statut: ppublish

Résumé

The lack of centralized data on severe asthma has resulted in a scarcity of information about the disease and its management. The development of a common data collection tool for the International Severe Asthma Registry (ISAR) will enable standardized data collection, subsequently enabling data interoperability. To create a standardized list of variables for the first international registry for severe asthma via expert consensus. A modified Delphi process was used to reach consensus on a minimum set of variables to capture in ISAR: the core variables. The Delphi panel brought together 27 international experts in the field of severe asthma research. The process consisted of 3 iterative rounds. In each round, all Delphi panel members were issued an electronic ISAR Delphi workbook to complete and return to the ISAR Delphi administrator. Workbooks and result summaries were anonymously distributed by the Delphi administrator to all panel members at subsequent rounds. Finalization of the core variable list was facilitated by 2 face-to-face meetings. Of the initial 747 selected variables, the Delphi panel reached a consensus on 95. The chosen variables will allow severe asthma to be assessed against patient demographics and medical history, patient-reported outcomes, diagnostic information, and clinical characteristics. Physician-reported outcomes such as nonadherence and information about treatment and management strategies will also be recorded. This is the first global attempt to generate an ISAR using a common set of core variables to ensure that data collected across all participating countries are standardized.

Sections du résumé

BACKGROUND
The lack of centralized data on severe asthma has resulted in a scarcity of information about the disease and its management. The development of a common data collection tool for the International Severe Asthma Registry (ISAR) will enable standardized data collection, subsequently enabling data interoperability.
OBJECTIVES
To create a standardized list of variables for the first international registry for severe asthma via expert consensus.
METHODS
A modified Delphi process was used to reach consensus on a minimum set of variables to capture in ISAR: the core variables. The Delphi panel brought together 27 international experts in the field of severe asthma research. The process consisted of 3 iterative rounds. In each round, all Delphi panel members were issued an electronic ISAR Delphi workbook to complete and return to the ISAR Delphi administrator. Workbooks and result summaries were anonymously distributed by the Delphi administrator to all panel members at subsequent rounds. Finalization of the core variable list was facilitated by 2 face-to-face meetings.
RESULTS
Of the initial 747 selected variables, the Delphi panel reached a consensus on 95. The chosen variables will allow severe asthma to be assessed against patient demographics and medical history, patient-reported outcomes, diagnostic information, and clinical characteristics. Physician-reported outcomes such as nonadherence and information about treatment and management strategies will also be recorded.
CONCLUSIONS
This is the first global attempt to generate an ISAR using a common set of core variables to ensure that data collected across all participating countries are standardized.

Identifiants

pubmed: 30179741
pii: S2213-2198(18)30552-X
doi: 10.1016/j.jaip.2018.08.016
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

578-588.e2

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Copyright © 2018 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Auteurs

Lakmini Bulathsinhala (L)

Optimum Patient Care, Cambridge, UK.

Nevaashni Eleangovan (N)

Optimum Patient Care, Cambridge, UK.

Liam G Heaney (LG)

UK Severe Asthma Network and National Registry, Queen's University Belfast, Belfast, Northern Ireland, UK.

Andrew Menzies-Gow (A)

UK Severe Asthma Network and National Registry, Royal Brompton & Harefield National Health Service (NHS) Foundation Trust, London, UK.

Peter G Gibson (PG)

Australasian Severe Asthma Network, Priority Research Centre for Healthy Lungs, University of Newcastle, Newcastle, NSW, Australia; Department of Respiratory and Sleep Medicine, Hunter Medical Research Institute, John Hunter Hospital, New Lambton Heights, NSW, Australia.

Matthew Peters (M)

University of Sydney Medical School, Sydney, NSW, Australia.

Mark Hew (M)

Allergy, Asthma & Clinical Immunology Service, Alfred Health, Melbourne, Australia.

Job F M van Boven (JFM)

Department of General Practice, Groningen Research Institute for Asthma and COPD (GRIAC), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Lauri Lehtimäki (L)

Allergy Centre, Tampere University Hospital, University of Tampere, Tampere, Finland.

Eric van Ganse (E)

Claude Bernard University Lyon, Lyon, France.

Manon Belhassen (M)

Claude Bernard University Lyon, Lyon, France.

Erin S Harvey (ES)

Australasian Severe Asthma Network, Priority Research Centre for Healthy Lungs, University of Newcastle, Newcastle, NSW, Australia; Department of Respiratory and Sleep Medicine, Hunter Medical Research Institute, John Hunter Hospital, New Lambton Heights, NSW, Australia.

Luis Perez de Llano (L)

Pneumology Service, Hospital Universitario Lucus Augusti, Lugo, Spain.

Anke H Maitland-van der Zee (AH)

Amsterdam University Medical Center, University of Amsterdam, Department of Respiratory Medicine, Amsterdam, The Netherlands.

Nikolaos G Papadopoulos (NG)

University of Athens, Athens, Greece; University of Manchester, Manchester, UK.

J Mark FitzGerald (JM)

The Institute for Heart Lung Health, Vancouver, BC, Canada.

Celeste Porsbjerg (C)

Bispebjerg Hospital, Copenhagen University, Copenhagen, Denmark.

G Walter Canonica (GW)

Personalized Medicine Asthma & Allergy Clinic, Humanitas University & Research Hospital, Milan, Italy; SANI-Severe Asthma Network Italy, Italy.

Vibeke Backer (V)

Bispebjerg Hospital, Copenhagen University, Copenhagen, Denmark.

Chin Kook Rhee (CK)

The Catholic University of Korea, Seoul, South Korea.

Katia M C Verhamme (KMC)

Erasmus Medical Center, Rotterdam, The Netherlands.

Roland Buhl (R)

Mainz University Hospital, Mainz, Germany.

Borja G Cosio (BG)

Son Espases University Hospital-IdISBa-Ciberes, Mallorca, Spain.

Victoria Carter (V)

Optimum Patient Care, Cambridge, UK.

Chris Price (C)

Optimum Patient Care, Cambridge, UK.

Thao Le (T)

Optimum Patient Care, Cambridge, UK.

Martina Stagno d'Alcontres (M)

Observational and Pragmatic Research Institute, Singapore.

Gokul Gopalan (G)

AstraZeneca, Short Hills, NJ.

Trung N Tran (TN)

AstraZeneca, Short Hills, NJ.

David Price (D)

Optimum Patient Care, Cambridge, UK; Observational and Pragmatic Research Institute, Singapore; Academic Primary Care, University of Aberdeen, Aberdeen, UK. Electronic address: dprice@opri.sg.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH